# A Study to Evaluate the Similarity in Pharmacokinetics and Safety of IBI310 and Ipilimumab（YERVOY）in Adult Healthy Chinese Male Volunteers

> **NCT04868760** · PHASE1 · COMPLETED · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 148 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** Ipilimumab
- **DRUG:** IBI310

## Key facts

- **NCT ID:** NCT04868760
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-31
- **Primary completion:** 2022-05-02
- **Final completion:** 2022-05-02
- **Target enrollment:** 148 (ACTUAL)
- **Last updated:** 2025-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04868760

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04868760, "A Study to Evaluate the Similarity in Pharmacokinetics and Safety of IBI310 and Ipilimumab（YERVOY）in Adult Healthy Chinese Male Volunteers". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT04868760. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*